Bile acid secretion in cystic fibrosis: evidence for a defect unrelated to fat malabsorption

Z WEIZMAN, P R DURIE, H R KOPELMAN, SHIRLY M VESELY AND G G FORSTNER

From the Gastrointestinal Division, Department of Paediatrics, and Cystic Fibrosis Research Centre, The Hospital for Sick Children, Toronto, Canada

SUMMARY In order to define basic biliary defects not related to steatorrhoea in cystic fibrosis, we studied 12 control and 18 cystic fibrosis subjects, with a wide range of pancreatic function. Duodenal aspirates were collected over three consecutive 20 minute periods, during continuous intravenous infusion of cholecystokinin and secretin using a marker perfusion technique, and analysed for pancreatic enzyme output (colipase, lipase, trypsin), bile acid output and concentration, and biliary lipids. Cystic fibrosis patients, at all levels of pancreatic function, had significantly reduced total bile acid output (μmol/kg/h) with delayed appearance of the bile acid peak, compared with control subjects. Actual duodenal bile acid concentrations were significantly higher in cystic fibrosis subjects than in controls, however, probably because of the markedly reduced water output shown in these patients. The lithogenic index was not raised in cystic fibrosis patients at any level of pancreatic function. The reduced bile acid output and the delayed peak appearance probably reflect a defect in gall bladder responsiveness which is independent of pancreatic function and steatorrhoea. Whether this defect is related to gall bladder filling or a defective peptide hormone response awaits further study.

Patients with cystic fibrosis are known to have a variety of bile acid abnormalities, including increased faecal bile acid losses, reduced bile acid pool size, reduced duodenal bile acid concentration and increased bile salt glycine:taurine ratios. Cystic fibrosis bile has also been reported to be lithogenic. Almost all of the abnormalities appear to be associated with exocrine pancreatic insufficiency and steatorrhoea, and have been reported to become normal with an improvement of fat malabsorption after oral pancreatic enzyme therapy.

Approximately 10–15% of cystic fibrosis patients do not have steatorrhoea and our studies have shown that these patients possess a very wide range of exocrine pancreatic function with enzyme secretion ranging from 2–100% of normal values. Studies of biliary secretion in this cystic fibrosis population would be very helpful in clarifying pathophysiological mechanisms of bile secretion as any defect would be independent of steatorrhoea. We have shown that these patients have defects in bicarbonate and water secretion which contribute to increased concentrations of protein in pancreaticobiliary secretions and possibly to ductal plugging. Unfortunately none of the previous studies related to bile acid secretion has attempted to correlate findings with the actual level of pancreatic function, and only limited data are available for cystic fibrosis patients without steatorrhoea. Weber et al showed that the faecal bile acid output of six cystic fibrosis patients without steatorrhoea was almost identical to that of controls. In contrast, a study of Fondacaro et al suggested that an ileal mucosal defect of taurocholic uptake was present in vitro.

In the present study we have analysed bile acid output during pancreatic function testing of cystic fibrosis patients who have a wide range of exocrine pancreatic function, including patients with and without steatorrhoea. Bile acid output in the cystic fibrosis patients has been compared with a group of subjects without cystic fibrosis who had a similar range of pancreatic function.
Methods

Subjects

We studied 18 patients with cystic fibrosis, aged 21·7±6·9 years (range 13–33 years) and 12 subjects without cystic fibrosis aged 20·9±5·6 years (range 13–32 years). Male to female ratios in the two groups were 9:9 and 5:7 respectively. The diagnosis of cystic fibrosis was established by clinical symptoms and signs, chest roentgenograms and pulmonary function abnormalities, together with sweat chloride levels consistently greater than 60 mmol/l. The 12 non-cystic fibrosis subjects in the control group consisted of four patients with Shwachman’s syndrome, a patient with coeliac disease and exocrine pancreatic insufficiency, one patient, who after investigation had no gastrointestinal disease, and six normal volunteers. The normal volunteers were studied after approval by the Human Experimentation Committee of the Hospital for Sick Children, Toronto. Subjects with malnutrition or obesity were excluded. Fasting serum bile acid concentrations, serum bilirubin, alkaline phosphatase and SGOT were obtained in all patients and were within normal limits.

Assessment of exocrine pancreatic function

Faecal fat output was estimated in three to five day stool collections by the method of van der Kamer and expressed as percentage of fat intake determined by recording and weighing food and reference to standard content tables. For the purposes of this study, patients were divided into two groups. Patients with faecal fat output of more than 7% were defined as having pancreatic insufficiency and those with faecal fat less than or equal to 7% as having pancreatic sufficiency, indicating that they possessed sufficient residual pancreatic function to achieve normal fat absorption.

Pancreaticobiliary secretions were defined quantitatively by a stimulation test using a previously described technique. After an overnight fast, a double lumen tube was inserted into the duodenum under fluoroscopic control. The tube was constructed so that one lumen opened approximately at the ampulla of Vater and the other, which contained several ports, was positioned distally at the ligament of Treitz. Through the proximal opening, a non-absorbable marker solution (0·5 ml bromosulphthalein in 250 ml of 5% Mannitol) was infused into the duodenum at a constant rate of 1·6 ml/min throughout the test. Duodenal juice mixed with the marker solution was aspirated throughout the distal ports by intermittent Gomco suction (Gomco Surgical Manufacturing Corp, Buffalo, New York) and collected over four 20 minute collection periods into flasks on ice. After an initial 20 minute perfusion to remove duodenal content, duodenal aspirate was collected for three consecutive 20 minute periods during a continuous intravenous infusion of secretin and pancreozymin (Boots Pure Drug Company, Nottingham, UK), both at a dose of 0·125 U/kg/body weight/min. Throughout the test, gastric juice was aspirated through a separate nasogastric tube by low Gomco suction to prevent contamination of duodenal contents.

Assays

Duodenal aspirates were analysed for colipase, lipase, and trypsin as described previously. Bromosulphthalein (BSP) concentration was determined by a colorimetric assay, so that the volume correction factor could be calculated. Pancreatic enzyme output was expressed in U/kg body weight/h.

Duodenal bile acids were measured with a modified 3-alpha-hydroxysteroid dehydrogenase method. Cholesterol was determined as described by Carr and Drekter and phospholipid phosphorus by the method of Bartlett. All determinations were carried out in duplicate on separate aliquots. The lithogenic index for cholesterol was calculated as described.BILE acid output

The mean bile acid output per 20 minute collection was expressed in μmol/kg body weight/min.

Results

Exocrine pancreatic function

A summary of pancreatic function data for all subjects is given in Table 1. Five cystic fibrosis patients had pancreatic insufficiency (CF–PI) and 13 had pancreatic sufficiency (CF–PS). Of the 12 subjects without cystic fibrosis, only two, a patient with Shwachman’s syndrome and a patient with coeliac disease and associated exocrine pancreatic insufficiency, had steatorrhoea. As illustrated in Table 1, there was a wide range of pancreatic function for cystic fibrosis as well as for control subjects.

Bile acid output

The mean bile acid output per 20 minute collection...
period is shown for all control, CF–PS and CF–PI subjects in Fig. 1. In the first two periods, output in both cystic fibrosis groups was significantly lower than that of the controls. As a group, the patients without steatorrhoea (CF–PS), like the control subjects, had the greatest bile acid output in the first period and the smallest bile acid output in the third period. The bile acid output in CF patients with steatorrhoea (CF–PI) changed relatively little from period to period.

A comparison of individual bile acid output values in the three collection periods revealed that while eight of the 12 (67%) control subjects showed a peak bile acid output in period I, only 5/18 (28%) in the cystic fibrosis group showed a similar pattern (p<0.02). Thus, most of the cystic fibrosis subjects had a late bile acid output peak, in period II or III, or no peak at all. Bile acid output values for cystic fibrosis subjects were significantly reduced when compared with non-cystic fibrosis values, for either total bile acid output from all three periods (Fig. 2a) or peak bile acid output (Fig. 2b), (p<0.001 and p<0.01 respectively). Regression analyses performed for total bile acid output or peak bile acid output against age or several pancreatic function parameters (colipase, lipase or trypsin output) revealed no correlation (r<0.2, p=NS). There was a significant correlation when total bile acid output was plotted versus total water output (r=0.50, p<0.01).

---

Table 1  Range of exocrine pancreatic function in all subjects

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n</th>
<th>Trypsin output*</th>
<th>Lipase output*</th>
<th>Colipase output*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cystic fibrosis</td>
<td>PS</td>
<td>13</td>
<td>16-1838</td>
<td>220-15005</td>
</tr>
<tr>
<td></td>
<td>PI</td>
<td>5</td>
<td>0-4</td>
<td>0-12</td>
</tr>
<tr>
<td>Control</td>
<td>PS</td>
<td>10</td>
<td>19-3591</td>
<td>323-45922</td>
</tr>
<tr>
<td></td>
<td>PI</td>
<td>2</td>
<td>2-51</td>
<td>24-467</td>
</tr>
</tbody>
</table>

* = units/kg/h.

---

Fig. 1  Mean bile acid output data for the three periods for control subjects (▲), CF–PS (●) and CF–PI (○) subjects, in periods I and II are significantly smaller in both cystic fibrosis groups than controls. * = p<0.05.

Fig. 2  Total bile acid output (A) and peak bile acid output (B) in control subjects without steatorrhoea (▲) and control subjects with steatorrhoea (△), CF–PS (●), and CF–PI (○) subjects. Means are indicated by short horizontal lines. Total and peak bile acid output were significantly lower in cystic fibrosis patients. ** = p<0.01, *** = p<0.001.
**Bile Acid Concentration**

As illustrated in Table 2, mean bile acid concentrations in both CF-PS and CF-PI samples were significantly higher than in control samples (p<0.02 and p<0.05 respectively). When compared with controls, water output was significantly reduced in both CF-PS and CF-PI patients (p<0.0001 for both).

**Bile Lithogenicity**

Mean lithogenic indices for individual periods and for the period with the highest bile acid output are given in Table 3. Although mean values in the CF-PI patients are lower than the means for control and CF-PS patients, this difference did not reach statistical significance. There was no significant difference between control and cystic fibrosis values.

Bile acid output values for all three periods were plotted against lithogenic index (Fig. 3). The overall pattern for both non-CF and CF subjects (36 and 54 data points respectively) revealed little change in lithogenicity over a wide range of bile acid output. Exceptionally high indices were found in only three samples, all in periods with very low bile acid outputs. The high values were from aspirates in period III from three different normal volunteers. With the exception of these values, there was no correlation between bile acid output and lithogenicity in either the cystic fibrosis or non-cystic fibrosis samples. No correlation was found as well between lithogenic index and age or trypsin, lipase, and colipase output.

**Table 2** Duodenal bile acid (BA) concentration and water output data

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n</th>
<th>BA concentration (mmol/l)</th>
<th>Water output (ml/kg/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>12</td>
<td>8.2±5.6</td>
<td>7.5±2.0</td>
</tr>
<tr>
<td>CF-PS</td>
<td>13</td>
<td>16.6±9.8*</td>
<td>2.3±1.2*</td>
</tr>
<tr>
<td>CF-PI</td>
<td>5</td>
<td>36.4±29.4*</td>
<td>0.9±0.7*</td>
</tr>
</tbody>
</table>

From controls *p<0.05, †p<0.002, ‡p<0.0001.

**Discussion**

We have shown that bile acid output is significantly reduced in cystic fibrosis patients when compared with control subjects. Furthermore, the peak bile acid output per 20 minute period is significantly lower in cystic fibrosis patients and peak rates of bile acid output are attained more slowly after stimulation. Cystic fibrosis patients with normal fat absorption as well as patients with steatorrhea exhibited these defects indicating that they are not related to pancreatic insufficiency. The significant correlation between water output and bile acid output supports this conclusion, because we have previously shown a decreased water output in cystic fibrosis, independent of pancreatic function.

Previous studies have described several gall bladder abnormalities in cystic fibrosis, such as hypoplastic gall bladder,

**Table 3** Comparison of lithogenic indices in the three periods and in peak bile acid output (BAO) period

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Period I</th>
<th>Period II</th>
<th>Period III</th>
<th>Peak BAO period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls (n=12)</td>
<td>0.9±0.4</td>
<td>0.9±0.4</td>
<td>1.3±1.0</td>
<td>0.9±0.3</td>
</tr>
<tr>
<td>CF-PS (n=13)</td>
<td>1.2±0.4*</td>
<td>1.1±0.4*</td>
<td>1.1±0.5*</td>
<td>1.0±0.4*</td>
</tr>
<tr>
<td>CF-PI (n=5)</td>
<td>0.7±0.4</td>
<td>0.6±0.3*</td>
<td>0.6±0.3*</td>
<td>0.6±0.3*</td>
</tr>
</tbody>
</table>

From controls, *p=not significant.
Bile acid secretion in cystic fibrosis: Evidence for a defect unrelated to fat malabsorption

Cystic fibrosis, as it has been recently reported that endogenous release of this hormone showed no significant difference from controls. A poor contractile response, however, may not be the only cause for diminished bile acid output in cystic fibrosis, as reduced filling of the gall bladder could have a similar effect. A primary ileal mucosal defect in bile acid uptake, as suggested by Fondacaro et al., might affect bile-acid pool size and gall bladder filling and cannot be excluded. Other parameters of bile acid kinetics like bile acid pool size, recycling frequency of bile acids and bile acid profile (G/T ratio, trihydroxy/dihydroxy ratio etc) have not been studied in CF-PS patients and should be evaluated in future studies.

After an overnight fast most of the bile acid pool is stored in the gall bladder, awaiting an adequate stimulus for gall bladder contraction in order to be secreted into the duodenum. The dose of pancreozymin administered during our stimulation test was previously shown to cause a significant contraction of the gall bladder in normal subjects, resulting in peak bile acid output. It should be noted that the aspiration of duodenal content throughout the present study (under 80 minutes) should not affect bile acid output results because of interruption of the enterohepatic circulation as previous studies in normal individuals have shown that acute interruption of the enterohepatic circulation only interferes with bile acid secretion rate after 90 minutes.

In view of the significant reduction in bile acid output in cystic fibrosis subjects, we have evaluated the actual bile acid concentration throughout the present study. Mean bile acid concentration in cystic fibrosis patients was significantly higher than controls. As we have previously shown, cystic fibrosis subjects have reduced water output at all levels of pancreatic function. High bile acid concentrations are therefore probably the result of poor water output. As total bile acid output is reduced they do not necessarily reflect the CMC achieved during a meal. Data regarding postprandial bile-acid concentration values in cystic fibrosis are limited. Goodchild et al. showed a mean postprandial duodenal total bile acid concentration that was within normal limits in five CF-PI patients. In contrast, a study by Harries et al. described normal postprandial duodenal bile acid concentrations in two CF-PS patients, while two out of 11 CF-PI subjects revealed reduced concentrations.

Cholesterol gall stones are a well recognised complication of cystic fibrosis. The bile of CF-PI patients has been reported to be supersaturated with cholesterol and lithogenic. Lithogenicity of bile, however, has never been evaluated in CF-PS subjects. In the present study, no significant differences in lithogenicity were found when cystic fibrosis and control individuals were compared. Poststimulation duodenal bile is considered to be mainly of gall bladder origin, especially during the period of peak bile acid output, and therefore accurately represents the relative lipid composition of gall bladder bile. Thus, our data fail to show significant lithogenicity of cystic fibrosis gall bladder bile.

The three subjects who had very lithogenic bile during the period with lowest bile acid output (Fig. 3) presumably represent sampling of hepatic bile. During continuous stimulation the gall bladder remains tonically contracted with secretion of hepatic bile into the duodenum. Hepatic bile is well known to be oversaturated with cholesterol. Only one cystic fibrosis subject had a lithogenic index greater than 2, and this occurred without a diminished bile acid output. Surprisingly, CF-PI patients showed a mean lithogenic index smaller than CF-PS or control individuals. These results for CF-PI subjects are not in agreement with data presented by Roy et al., who showed an abnormally high molar percentage of cholesterol in fasting CF-PI bile which disappeared after pancreatic enzyme therapy, suggesting that it was secondary to steatorrhoea. Our results could represent real differences between the groups of patients studied or the different design of the two studies. Roy et al. suspended pancreatic enzyme therapy for one week before testing while our patients stopped this therapy only 48 hours before the study. It is possible that the 48 hour time interval was insufficient to reverse the effect of enzyme therapy. It should be noted, however, that our CF-PS patients were not on enzyme therapy. These patients had no evidence of lithogenic bile. Cholesterol supersaturation, when seen, therefore is probably a secondary result of untreated pancreatic steatorrhoea. Cholesterol supersaturation may not be the only cause of gall stones in cystic fibrosis. Other potential mechanisms such as abnormal gall bladder mucin, as shown in the small intestine, and high protein content of pancreaticobiliary secretion, may play a role in gall stone formation in cystic fibrosis and should be evaluated in future studies.

We are grateful for the thoughtful advice provided by Dr Steven Strasberg with regard to bile salt analyses.

References


